Duality Advisers, LP Apellis Pharmaceuticals, Inc. Transaction History

Duality Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$43.24 - $61.04 $1.13 Million - $1.6 Million	-26,234 Reduced 68.93%	11,823 $611,000
Q3 2022 Nov 03, 2022	BUY	$44.76 - $69.66 $1.7 Million - $2.65 Million	38,057 New	38,057 $2.6 Million
Q4 2021 Feb 02, 2022	SELL	$30.74 - $49.16 $3.42 Million - $5.46 Million	-111,100 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$31.4 - $69.84 $3.49 Million - $7.76 Million	111,100 New	111,100 $3.66 Million
Q2 2021 Aug 09, 2021	SELL	$40.9 - $64.9 $621,189 - $985,701	-15,188 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $619,670 - $871,639	15,188 New	15,188 $652,000
Q4 2020 Feb 09, 2021	SELL	$30.79 - $57.2 $270,952 - $503,360	-8,800 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$25.89 - $33.65 $227,832 - $296,120	8,800 New	8,800 $265,000

300

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.